BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan S, Wen L, Zhou J. Inhibitors of Influenza A Virus Polymerase. ACS Infect Dis 2018;4:218-23. [PMID: 29355011 DOI: 10.1021/acsinfecdis.7b00265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen W, Shao J, Ying Z, Du Y, Yu Y. Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit. Drug Discov Today 2022:S1359-6446(22)00085-X. [PMID: 35247593 DOI: 10.1016/j.drudis.2022.02.024] [Reference Citation Analysis]
2 Dufrasne F. Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals (Basel) 2021;15:28. [PMID: 35056085 DOI: 10.3390/ph15010028] [Reference Citation Analysis]
3 Massari S, Desantis J, Nizi MG, Cecchetti V, Tabarrini O. Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. ACS Infect Dis 2021;7:1332-50. [PMID: 33044059 DOI: 10.1021/acsinfecdis.0c00552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
4 Wang A, Li Y, Lv K, Gao R, Wang A, Yan H, Qin X, Xu S, Ma C, Jiang J, Wei Z, Zhang K, Liu M. Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. Eur J Med Chem 2021;222:113591. [PMID: 34126455 DOI: 10.1016/j.ejmech.2021.113591] [Reference Citation Analysis]
5 Abd Raman HS, Tan S, August JT, Khan AM. Dynamics of Influenza A (H5N1) virus protein sequence diversity. PeerJ 2020;7:e7954. [PMID: 32518710 DOI: 10.7717/peerj.7954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zhang J, Hu Y, Wu N, Wang J. Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay. ACS Chem Biol 2020;15:74-82. [PMID: 31714745 DOI: 10.1021/acschembio.9b00552] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
7 Zhang H, Zhou L, Amichai S, Zandi K, Cox B, Schinazi R, Amblard F. Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. Bioorg Med Chem Lett 2019;29:126639. [PMID: 31493987 DOI: 10.1016/j.bmcl.2019.126639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Tauran Y, Cerón-Carrasco JP, Rhimi M, Perret F, Kim B, Collard D, Coleman AW, Pérez-Sánchez H. Size and Flexibility Define the Inhibition of the H3N2 Influenza Endonuclease Enzyme by Calix[n]arenes. Antibiotics (Basel) 2019;8:E73. [PMID: 31163674 DOI: 10.3390/antibiotics8020073] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Melville K, Rodriguez T, Dobrovolny HM. Investigating Different Mechanisms of Action in Combination Therapy for Influenza. Front Pharmacol 2018;9:1207. [PMID: 30405419 DOI: 10.3389/fphar.2018.01207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dou D, Revol R, Östbye H, Wang H, Daniels R. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Front Immunol 2018;9:1581. [PMID: 30079062 DOI: 10.3389/fimmu.2018.01581] [Cited by in Crossref: 134] [Cited by in F6Publishing: 118] [Article Influence: 33.5] [Reference Citation Analysis]